Blueprint Medicines Corporation (BPMC)
Largest Insider Buys in Sector
BPMC Stock Price History Chart
BPMC Stock Performance
About Blueprint Medicines Corporation
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Insider Activity of Blueprint Medicines Corporation
Over the last 12 months, insiders at Blueprint Medicines Corporation have bought $0 and sold $39.48M worth of Blueprint Medicines Corporation stock.
On average, over the past 5 years, insiders at Blueprint Medicines Corporation have bought $349,105 and sold $21.15M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,100 shares for transaction amount of $48,378 was made by Haviland Kate (CHIEF EXECUTIVE OFFICER) on 2022‑11‑03.
List of Insider Buy and Sell Transactions, Blueprint Medicines Corporation
| 2024-11-29 | Sale | CHIEF EXECUTIVE OFFICER | 2,353 0.0037% | $96.60 | $227,304 | +0.15% | ||
| 2024-11-27 | Sale | CHIEF OPERATING OFFICER | 2,274 0.0036% | $95.10 | $216,257 | +1.42% | ||
| 2024-11-21 | Sale | director | 9,824 0.0151% | $94.87 | $932,003 | -1.12% | ||
| 2024-11-20 | Sale | director | 10,000 0.0157% | $93.77 | $937,655 | +1.22% | ||
| 2024-11-07 | Sale | director | 5,000 0.0079% | $102.00 | $510,000 | -4.94% | ||
| 2024-10-03 | Sale | PRESIDENT, R & D | 3,633 0.0058% | $89.32 | $324,500 | +5.46% | ||
| 2024-09-09 | Sale | director | 19,702 0.0308% | $85.57 | $1.69M | +4.43% | ||
| 2024-08-15 | Sale | CHIEF FINANCIAL OFFICER | 4,409 0.0071% | $95.23 | $419,869 | 0.00% | ||
| 2024-08-05 | Sale | CHIEF COMMERCIAL OFFICER | 41,913 0.0663% | $93.19 | $3.91M | -0.84% | ||
| 2024-07-05 | Sale | CHIEF PEOPLE OFFICER | 3,850 0.0066% | $111.20 | $428,120 | 0.00% | ||
| 2024-07-03 | Sale | CHIEF PEOPLE OFFICER | 8,817 0.0151% | $111.29 | $981,244 | 0.00% | ||
| 2024-06-28 | Sale | CHIEF PEOPLE OFFICER | 333 0.0006% | $111.15 | $37,013 | 0.00% | ||
| 2024-06-21 | Sale | CHIEF PEOPLE OFFICER | 74,034 0.1169% | $104.19 | $7.71M | -10.72% | ||
| 2024-06-05 | Sale | CHIEF SCIENTIFIC OFFICER | 4,000 0.0063% | $105.13 | $420,520 | -11.28% | ||
| 2024-06-04 | Sale | CHIEF MEDICAL OFFICER | 2,424 0.004% | $104.91 | $254,302 | -7.86% | ||
| 2024-06-03 | Sale | CHIEF SCIENTIFIC OFFICER | 2,436 0.0039% | $106.43 | $259,263 | -10.52% | ||
| 2024-06-03 | Sale | CHIEF MEDICAL OFFICER | 4,922 0.008% | $106.43 | $523,848 | -10.52% | ||
| 2024-05-31 | Sale | CHIEF MEDICAL OFFICER | 34,108 0.0547% | $105.91 | $3.61M | -10.93% | ||
| 2024-05-15 | Sale | CHIEF FINANCIAL OFFICER | 3,850 0.0062% | $106.95 | $411,772 | -10.93% | ||
| 2024-05-15 | Sale | PRINCIPAL ACCOUNTING OFFICER | 5,856 0.0094% | $106.96 | $626,379 | -10.93% |
Insider Historical Profitability
| Albers Jeffrey W. | director | 157557 0.248% | $95.66 | 0 | 55 | |
| Haviland Kate | CHIEF EXECUTIVE OFFICER | 150824 0.2374% | $95.66 | 1 | 27 | +10.84% |
| Rossi Christina | CHIEF OPERATING OFFICER | 71657 0.1128% | $95.66 | 0 | 9 | |
| Namouni Fouad | PRESIDENT, R & D | 69070 0.1087% | $95.66 | 0 | 7 | |
| Landsittel Michael | CHIEF FINANCIAL OFFICER | 67208 0.1058% | $95.66 | 0 | 10 | |
| McCain Tracey L | EVP AND CHIEF LEGAL OFFICER | 60498 0.0952% | $95.66 | 0 | 9 | |
| Durso-Bumpus Debra | CHIEF PEOPLE OFFICER | 43763 0.0689% | $95.66 | 0 | 15 | |
| Carter Percy H. | CHIEF SCIENTIFIC OFFICER | 41895 0.0659% | $95.66 | 0 | 6 | |
| Lee Philina | CHIEF COMMERCIAL OFFICER | 34729 0.0547% | $95.66 | 0 | 4 | |
| Murray Christopher K. | CHIEF TECHNICAL OPERATIONS | 33853 0.0533% | $95.66 | 0 | 11 | |
| Hewes L. Becker | CHIEF MEDICAL OFFICER | 29514 0.0465% | $95.66 | 0 | 14 | |
| Hurley Ariel | PRINCIPAL ACCOUNTING OFFICER | 14913 0.0235% | $95.66 | 0 | 38 | |
| COATS LONNEL | director | 2242 0.0035% | $95.66 | 0 | 3 | |
| Third Rock Ventures II, L.P. | 10 percent owner | 4453753 7.0109% | $95.66 | 0 | 1 | |
| FMR LLC | 264898 0.417% | $95.66 | 1 | 9 | +9.46% | |
| LYNCH DANIEL | director | 174342 0.2744% | $95.66 | 0 | 10 | |
| LEVIN MARK J | 10 percent owner | 111244 0.1751% | $95.66 | 0 | 1 | |
| Borisy Alexis | director | 60906 0.0959% | $95.66 | 0 | 7 | |
| Lengauer Christoph | Chief Scientific Officer | 56657 0.0892% | $95.66 | 0 | 8 | |
| Lydon Nicholas | director | 37425 0.0589% | $95.66 | 0 | 11 | |
| Boral Anthony L. | Chief Medical Officer | 28147 0.0443% | $95.66 | 0 | 11 | |
| Dorsch Marion | Chief Scientific Officer | 15250 0.024% | $95.66 | 0 | 14 | |
| Goldberg Mark Alan | 10812 0.017% | $95.66 | 1 | 6 | <0.0001% | |
| Demetri George | 5822 0.0092% | $95.66 | 1 | 9 | <0.0001% | |
| Rowland Charles A Jr | director | 3562 0.0056% | $95.66 | 0 | 4 | |
| STARR KEVIN P | 10 percent owner | 0 0% | $95.66 | 0 | 1 |
Institutional Investor Ownership
| BlackRock | $611.61M | 10.3 | 6.45M | -2.08% | -$12.97M | 0.01 | |
| The Vanguard Group | $598.56M | 10.08 | 6.31M | +3.19% | +$18.5M | 0.01 | |
| T. Rowe Price | $592.95M | 9.98 | 6.25M | +15.14% | +$77.96M | 0.07 | |
| Fidelity Investments | $490.38M | 8.26 | 5.17M | +18.89% | +$77.9M | 0.03 | |
| Wellington Management Company | $396.05M | 6.67 | 4.18M | -2.37% | -$9.6M | 0.07 | |
| ROCK SPRINGS CAPITAL MANAGEMENT, LP | $237M | 3.99 | 2.5M | -13.3% | -$36.34M | 6.17 | |
| State Street | $208M | 3.5 | 2.19M | -9.55% | -$21.96M | 0.01 | |
| William Blair Investment Management | $162.03M | 2.73 | 1.71M | -1.15% | -$1.88M | 0.42 | |
| Geode Capital Management | $130.08M | 2.19 | 1.37M | +3.31% | +$4.16M | 0.01 | |
| Lord Abbett | $125.06M | 2.11 | 1.32M | -9.04% | -$12.43M | 0.44 | |
| Macquarie Group | $124.38M | 2.09 | 1.31M | -16.43% | -$24.45M | 0.11 | |
| JPMorgan Chase | $124.4M | 2.09 | 1.31M | -13.71% | -$19.76M | 0.01 | |
| AllianceBernstein | $114.17M | 1.92 | 1.2M | -11.37% | -$14.65M | 0.04 | |
| Morgan Stanley | $100.43M | 1.69 | 1.06M | -9.35% | -$10.36M | 0.01 | |
| T Rowe Price Investment Management Inc | $95.16M | 1.6 | 1M | -37.25% | -$56.5M | 0.06 | |
| Polar Capital | $82.05M | 1.38 | 865,000 | 0% | +$0 | 0.45 | |
| Woodline Partners LP | $78.47M | 1.32 | 827,173 | +1.56% | +$1.2M | 0.67 | |
| Invesco | $76.8M | 1.29 | 809,600 | +93.88% | +$37.19M | 0.02 | |
| Alkeon Capital Management Llc | $75.31M | 1.27 | 793,928 | +23.3% | +$14.23M | 0.42 | |
| American Century Investments | $73.05M | 1.23 | 770,133 | +8.21% | +$5.54M | 0.05 | |
| Holocene Advisors, LP | $67.85M | 1.14 | 715,303 | New | +$67.85M | 0.25 | |
| Brown Advisory | $63.97M | 1.08 | 674,362 | -0.82% | -$527,232.03 | 0.09 | |
| Goldman Sachs | $53.75M | 0.91 | 566,654 | -1.97% | -$1.08M | 0.01 | |
| Northern Trust | $53.02M | 0.89 | 558,890 | -2.55% | -$1.39M | 0.01 | |
| Charles Schwab | $47.54M | 0.8 | 501,135 | +5.27% | +$2.38M | 0.01 | |
| Hood River Capital Management LLC | $44.6M | 0.75 | 470,126 | +6.84% | +$2.86M | 1 | |
| Avidity Partners Management Lp | $40.41M | 0.68 | 426,000 | -30.73% | -$17.93M | 1.54 | |
| Man Group Plc | $38.79M | 0.65 | 408,880 | +8.15% | +$2.92M | 0.1 | |
| Emerald Advisers, Inc. | $38.22M | 0.64 | 402,910 | -13.62% | -$6.03M | 1.55 | |
| Td Asset Management Inc | $36.38M | 0.61 | 383,470 | +29.59% | +$8.31M | 0.03 | |
| D. E. Shaw & Co. | $35.68M | 0.6 | 376,177 | +7.69% | +$2.55M | 0.03 | |
| Novo Holdings A/S | $34.02M | 0.57 | 358,626 | -0.14% | -$47,430.00 | 2.38 | |
| Bank of America | $31.85M | 0.54 | 335,775 | +7.89% | +$2.33M | <0.01 | |
| Fisher Asset Management Llc | $31.79M | 0.54 | 335,128 | +2.59% | +$802,895.01 | 0.02 | |
| Casdin Capital | $30.96M | 0.52 | 326,378 | 0% | +$0 | 1.53 | |
| Ensign Peak Advisors Inc | $30.31M | 0.51 | 319,528 | +41.93% | +$8.96M | 0.05 | |
| EMERALD MUTUAL FUND ADVISERS TRUST | $29.96M | 0.5 | 315,819 | -16.95% | -$6.11M | 1.57 | |
| Point72 Asset Management | $26.54M | 0.45 | 279,768 | +591.9% | +$22.7M | 0.04 | |
| Nuveen | $25.27M | 0.43 | 266,347 | -0.15% | -$38,987.46 | 0.01 | |
| Panagora | $24.99M | 0.42 | 263,474 | -2.6% | -$667,434.97 | 0.13 | |
| BNY Mellon | $22.88M | 0.39 | 241,190 | -7.43% | -$1.84M | <0.01 | |
| Ubs Asset Management Americas Inc | $22.26M | 0.38 | 234,615 | -1.91% | -$432,371.90 | 0.01 | |
| Eventide Asset Management | $21.98M | 0.37 | 231,685 | -25.83% | -$7.65M | 0.36 | |
| Marshall Wace | $21.85M | 0.37 | 230,292 | New | +$21.85M | 0.02 | |
| HERITAGE ASSET MANAGEMENT INC | $21.33M | 0.35 | 221,251 | -4.38% | -$978,180.88 | 0.11 | |
| Voloridge Investment Management, LLC | $20.72M | 0.35 | 218,436 | +54.93% | +$7.35M | 0.08 | |
| Integral Health Asset Management Llc | $19.92M | 0.34 | 210,000 | +50% | +$6.64M | 2 | |
| Victory Capital Management Inc | $19.56M | 0.33 | 206,199 | +57.34% | +$7.13M | 0.02 | |
| The Manufacturers Life Insurance Company | $17.48M | 0.29 | 184,220 | +35.49% | +$4.58M | 0.02 | |
| Spyglass Capital Management LLC | $17.28M | 0.29 | 182,151 | -28.52% | -$6.89M | 12.95 |